Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic
DGAP-News: Evotec receives € 7.5 m grant for development of COVID-19 therapeutic
Acadia Healthcare Expands Footprint in Illinois Through Real Estate Purchase and Establishes New Behavioral Healthcare System Named Montrose Behavioral Health Hospital: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Expands Footprint in Illinois Through Real Estate Purchase and Establishes New Behavioral Healthcare System Named Montrose Behavioral Health Hospital


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has completed the acquisition of the real estate for three currently non-operational facilities, including one adult hospital

Acadia Healthcare Forms Joint Venture with Fairview Health Services: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture with Fairview Health Services


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Fairview Health Services, one of Minnesota’s leading health systems. Through this partnership

Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases
Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab
Gerresheimer AG: Gerresheimer schließt Vereinbarung mit bekanntem US-BioTech Unternehmen zur Entwicklung einer innovativen Pumpe ab
DGAP-News: Evotec receives US$ 18 m grant for women's health: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec receives US$ 18 m grant for women's health
DGAP-News: Evotec receives US$ 18 m grant for women's health
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit
DGAP-News: Evotec erhält 18 Mio. US$ Förderung im Bereich Frauengesundheit
Acadia Healthcare Forms Joint Venture With SCL Health to Build a New Behavioral Health Facility in Denver Metro Area: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With SCL Health to Build a New Behavioral Health Facility in Denver Metro Area


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with SCL Health, one of Colorado’s premier healthcare systems. The new partnership will build a new

DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire


Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown

ICON Named Best Contract Research Organisation in Latest String of Industry Awards: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Named Best Contract Research Organisation in Latest String of Industry Awards


ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, is proud to

Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program


Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for

United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022


United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of

LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December

Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region


Orlando Health and Acadia Healthcare Company announced today that they have formed a joint venture designed to enhance and expand behavioral health services in the region.


This press release

Acadia Healthcare Forms Joint Venture With Orlando Health: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With Orlando Health


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Orlando Health, one of Central Florida’s premier health systems. With Acadia’s partnership

LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place